TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05165810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced adherence support [experimental]
Description: Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
Study: NCT05583565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory integration approach
Description: Sensory integration refers to how the nervous system receives messages from multimodal sensory information systems to maintain balance, posture, and balance by monitoring head movement and stabilizing the eyes about the environment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: conventional physiotherapy training programs such as the following: 1)Hand function training by locating the Grading of the hand and training this level until it is well developed to transfer to the next level according to 8 parameters (partner's height-shape-weight-texture -reaction time-speed-accuracy-number of trials).~2) equilibrium training by promoting posture reaction. 3)ADL activity training (nutrition training-dressing training-toilet training). 4) Functional skill training through walking (walking on sand, weight on legs, and Climbing stairs ).
Study: NCT06382831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Opioid free anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Control given Opioid balanced anesthesia
Study: NCT05454501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: For eight weeks, they will receive real-time online exercise training for 30 minutes, three days a week, with a peer group of 5-6 people. Before starting the exercise, physical activity will be monitored for seven days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: After the first face-to-face evaluation session, these patients and their families will receive a 1-hour patient education program specific to the disease and exercise. Information brochures containing physical activity and exercise recommendations will be given. They will be followed up with weekly phone calls throughout the study period. At the end of 8 weeks, the second evaluation interview will be held. Afterward, the patients in the control group will be able to participate in the online exercise training program if they request it.
Study: NCT05534685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intratracheal administration of surfactant/budesonide
Description: 328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: incidence of bronchopulmonary dysplasia
Description: . Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
Study: NCT05965778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2769
Description: T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed® Multi
Description: Hyaluronic acid
Study: NCT06558474

Intervention type: BEHAVIORAL
Intervention: Liberal post-dilatation strategy during PCI
Description: A liberal post-dilatation strategy for stent optimization during PCI will be implemented in multiple centers in the Netherlands.~This include an increase of post-dilatation use of at least 20% per operator, or a percentage of post-dilatation of at least 85%.~Operators will be asked to enforce a very low threshold for post-dilatation in general, with a mandatory HPNC post-dilatation for the following indications:~* In case of any calcification~* Delta of ≥ 0.5mm between the distal and proximal reference diameter of the treated coronary segment~* Stent length \>24 mm~* Signs of incomplete stentframe-deployment on angiography or StentBoost~* In case of CTO~* In case of bifurcation PCI (Left main and non-left main)~  * Proximal Optimisation Technique (POT) with NC balloon~ * Final Kissing Balloon dilatation (FKB) with preferentially first sequential high-pressure inflations and final low pressure kiss both with NC balloons
Study: NCT05089279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349
Description: QD, PO
Study: NCT06157255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 Inhalation Powder, 1 mg
Description: 3 mg dose, inhaled, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)
Description: 30 μg, intravenous, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)
Description: 4 mg, oral, fasted
Study: NCT05824988

Intervention type: OTHER
Intervention: Drug exposure
Description: Drug concentrations will be measured after one-month antimycobacterial treatment. Area under drug concentration-time curve (AUC) and maximum concentration (Cmax) will be calculated.
Study: NCT05890339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Proximal Gastrectomy With Double-flap Technique
Description: Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction
Description: Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
Study: NCT06112704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT05165810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced adherence support [experimental]
Description: Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced adherence support [experimental]
Description: Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
Study: NCT06640647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1005 injection or placebo
Description: HDM1005 injection or placebo isubcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1005 injection or placebo
Description: HDM1005 injection or placebo isubcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1005 injection or placebo
Description: HDM1005 injection or placebo isubcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1005 injection or placebo
Description: HDM1005 injection or placebo isubcutaneous injection once
Study: NCT06645249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone (Antiarrhythmic drug)
Description: Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone (Antiarrhythmic drug)
Description: Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring
Study: NCT04873908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified constraint-induced therapy
Description: Patients received conventional rehabilitation and modified constraint-induced therapy schedule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: Patients received conventional rehabilitation and Proprioceptive Training schedule

Intervention type: OTHER
Group type: OTHER
Intervention: conventional rehabilitation
Description: Patients received conventional rehabilitation schedule
Study: NCT06176586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mat Pilates Exercises
Description: The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
Study: NCT06349213

Intervention type: RADIATION
Intervention: FDOPA injection before PET imaging
Description: Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.

Intervention type: RADIATION
Intervention: FDOPA injection before PET imaging
Description: Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.

Intervention type: BEHAVIORAL
Intervention: Time perception tasks
Description: The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations

Intervention type: BEHAVIORAL
Intervention: Time perception tasks
Description: The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations

Intervention type: DEVICE
Intervention: fMRI imaging
Description: Imaging of brain structure during the completion of the time perception task

Intervention type: DEVICE
Intervention: fMRI imaging
Description: Imaging of brain structure during the completion of the time perception task

Intervention type: DEVICE
Intervention: EEG imaging
Description: Recording of neural dynamics during the completion of the time perception task

Intervention type: DEVICE
Intervention: EEG imaging
Description: Recording of neural dynamics during the completion of the time perception task

Intervention type: BEHAVIORAL
Intervention: 3 year follow-up
Description: Behavioral and EEG follow-up (for older adults only)
Study: NCT05165810

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine adherence support [usual care]
Description: Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine adherence support [usual care]
Description: Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
Study: NCT05220202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention Group (MOTIVATE)
Description: Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
Study: NCT04925024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lomecel-B medicinal signaling cells
Description: A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10\^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
Study: NCT06540976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive testing
Description: Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive testing
Description: Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive testing
Description: Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.
Study: NCT06119321

Intervention type: OTHER
Intervention: Pentacam, Corvis ST and Scansys
Description: morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST
Study: NCT05165810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine adherence support [usual care]
Description: Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine adherence support [usual care]
Description: Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
Study: NCT06119321

Intervention type: OTHER
Intervention: Pentacam, Corvis ST and Scansys
Description: morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST

Intervention type: OTHER
Intervention: Pentacam, Corvis ST and Scansys
Description: morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST
Study: NCT04724252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Arm
Study: NCT04770285

Intervention type: DEVICE
Group type: OTHER
Intervention: CT-152 - Digital Therapeutic
Description: CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham
Description: Sham mobile app was used by the participants as per the schedule specified in the respective arm.
Study: NCT06183567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedoanalgesia
Description: In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under sedoanalgesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedoanalgesia
Description: In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under sedoanalgesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under general anesthesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under general anesthesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
Study: NCT04522739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo to match spironolactone will be taken orally once per day for 12 months.
Study: NCT06539728

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces
Description: Participants will drop a saline solution with proteins onto the testing device. They will wait for it to dry and then report on the tactile sensation and overall feel of the surface. Feedback will include comparisons with the two reference surfaces. The primary goal is to determine the presence of mock COVID antigen in synthetic saliva using the device, which aligns with the goals of diagnostic testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomechanical Measurements
Description: Participants may have biomechanical measurements recorded, such as placing samples on a scale to measure downward force or using medical tape with a flexible wire to track finger motion. These measurements are likely aimed at objectively assessing how participants interact with the surfaces and their physical responses to tactile stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychophysical Tasks
Description: Participants may alternatively be asked to perform standardized psychophysical tasks, such as Two Alternative Forced Choice tests, Odd-Man Out tests, or Magnitude Estimation tests. These tasks will provide structured comparisons and quantitative data on participants' perception and preferences regarding tactile qualities. The tasks are designed to evaluate participants' perception and preferences regarding tactile qualities, which involves behavioral responses to sensory stimuli.
Study: NCT04458766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Description: This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.